Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

The pharmaceutical company on Thursday said it raised its full-year guidance for revenue in the year to a range of $45.8 billion to $46.8 billion, up from a previous forecast of $45.5 billion.

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

We published the book "Demystifying Psychiatry" in 2010. Although basic principles of psychiatric treatment remain unchanged, ...

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for schizophrenia.

Across Pennsylvania, families like those of Cody Balmer's, the suspect in the firebombing at the Governor's Residence, ...